Phase 3

Niraparib vs. TemozolomideA Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Sponsor:

Ivy Brain Tumor Center

Code:

NCT06388733

Conditions

Glioblastoma

GBM

Brain Neoplasms, Adult, Malignant

Brain Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Niraparib

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by Ivy Brain Tumor Center on 2026-07-01.